厄洛替尼对比长春瑞滨联合顺铂用于中国IIIA期EGFR突变阳性NSCLC辅助治疗的EVAN随机II期试验
EVAN研究纳入102例完全切除的IIIA期EGFR突变阳性NSCLC患者,随机接受辅助厄洛替尼或长春瑞滨联合顺铂化疗。研究表明酪氨酸激酶抑制剂可能作为辅助治疗发挥重要作用。
要点
- 厄洛替尼组3级及以上不良事件发生率12%,低于化疗组的26%。
- 该研究为II期试验,总生存数据尚不成熟,需进一步确认。
核心结论
- 与化疗相比,辅助厄洛替尼改善了EGFR突变阳性IIIA期NSCLC患者的2年无病生存率,且耐受性更好。
研究设计与样本
- 随机、开放标签、II期试验,纳入102例18-75岁完全切除的IIIA期EGFR突变阳性NSCLC患者,1:1随机分配至厄洛替尼组(n=51)或长春瑞滨联合顺铂化疗组(n=51)。
主要发现
- 厄洛替尼组任何级别不良事件发生率为58%(29/50),化疗组为65%(28/43);3级及以上不良事件分别为12%(6/50)和26%(11/43)。
- 厄洛替尼组最常见3级及以上不良事件为皮疹(2/50,4%),化疗组为中性粒细胞减少(7/43,16%)和骨髓抑制(4/43,9%);未报告治疗相关死亡。
关键数值与推荐
- 厄洛替尼用法:150 mg每日一次口服。
- 化疗方案:长春瑞滨25 mg/m2静脉注射(每21天周期第1、8天)联合顺铂75 mg/m2静脉注射(每21天周期第1天),共4周期。
临床怎么用
- 对于完全切除的IIIA期EGFR突变阳性NSCLC患者,辅助厄洛替尼可能作为化疗的替代选择,但需结合II期试验的局限性和总生存数据尚未成熟的情况个体化决策。
局限性
- 本研究为II期试验,样本量有限。
- 总生存数据尚不成熟,需要等待成熟的总生存结果。
- 研究为开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive stage IIIA NSCLC. METHODS: In this randomised, open-label, phase 2 trial, eligible patients aged 18-75 years who had undergone complete (R0) resection of histologically or pathologically confirmed stage IIIA EGFR mutation-positive NSCLC and had not received any previous anticancer therapies were enrolled. Patients were randomly assigned (1:1) to receive either adjuvant erlotinib (150 mg once daily administered orally) or vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m2 intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m2 intravenously on day 1 of each 21-day cycle]). Randomisation was done by Simon's minimisation with a random element and was stratified by EGFR activating mutation type (exon 19 vs 21), histology (adenocarcinoma vs non-adenocarcinoma), and smoking status (smoker vs non-smoker). The primary endpoint in the unblinded intention-to-treat analysis was 2-year disease-free survival. This ongoing study is registered with ClinicalTrials.gov, number NCT01683175. FINDINGS: Between Sept 8, 2012, and May 21, 2015, 102 patients from 16 centres across China were enrolled and randomly assigned to receive erlotinib (n=51) or chemotherapy (n=51). Median follow-up was 33·0 months (IQR 17·8-43·1). 2-year disease-free survival was 81·4% (95% CI 69·6-93·1) in the erlotinib group and 44·6% (26·9-62·4) in the chemotherapy group (relative risk 1·823 [95% CI 1·194-2·784; p=0·0054). The difference in 2-year disease-free survival between the groups was 36·7% (95% CI 15·5-58·0; p=0·0007). Adverse events of any grade occurred in 29 (58%) of 50 patients in the erlotinib group and 28 (65%) of 43 patients in the chemotherapy group. Grade 3 or worse adverse events occurred in six (12%) of 50 patients in the erlotinib group versus 11 (26%) of 43 in the chemotherapy group; the most common of these in the erlotinib group was rash (in two [4%] of 50 patients) and in the chemotherapy group were decreased neutrophil count (in seven [16%] of 43 patients) and myelosuppression (in four [9%]). No treatment-related deaths were reported. INTERPRETATION: Adjuvant erlotinib improved 2-year disease-free survival in patients with EGFR mutation-positive stage IIIA NSCLC compared with chemotherapy, with a better tolerability profile. This study suggests that tyrosine kinase inhibitors could have a potentially important role as adjuvant therapy in EGFR mutation-positive stage IIIA NSCLC. However, this trial was a phase 2 study. Mature overall survival data are also needed. Ongoing studies will hopefully confirm the role of adjuvant EGFR tyrosine kinase inhibitor therapy in patients with NSCLC. FUNDING: National Key Research and Development Program of China and Shanghai Roche Pharmaceuticals Ltd.
引用
- Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018. PMID: 30150014. doi:10.1016/S2213-2600(18)30277-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。